S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
The purposes of the study were to obtain further information about the optimal dose and the efficacy of Keppra in daily clinical practice, and to confirm the favorable safety and tolerability profiles of the drug observed during clinical development.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy|
- Percentage reduction in seizure frequency. [ Time Frame: 16-week treatment period ]
- To further assess safety.
- The patient-weighted Quality Of Life In Epilepsy inventory.
|Study Start Date:||August 2000|
|Study Completion Date:||February 2004|
|Primary Completion Date:||February 2004 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00630968
|Study Director:||UCB Clinical Trial Call Center||+1 877 822 9493 (UCB)|